Cencora (COR) Expected to Post Quarterly Earnings on Wednesday

Cencora (NYSE:COR) is expected to be announcing its Q4 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $4.58 per share and revenue of $87.95 billion for the quarter. Investors can find conference call details on the company’s upcoming Q4 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, topping the consensus estimate of $4.35 by $0.13. The firm had revenue of $84.75 billion during the quarter, compared to analysts’ expectations of $84.31 billion. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period last year, the business posted $4.00 earnings per share. On average, analysts expect Cencora to post $17.87 EPS for the current fiscal year and $19.77 EPS for the next fiscal year.

Cencora Stock Down 1.5%

Shares of COR stock opened at $325.09 on Wednesday. The stock has a market cap of $62.04 billion, a price-to-earnings ratio of 24.15 and a beta of 0.58. Cencora has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The firm’s 50 day moving average price is $322.60 and its two-hundred day moving average price is $317.67.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Friday, August 14th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 14th. Cencora’s dividend payout ratio (DPR) is presently 17.83%.

Insider Transactions at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the transaction, the executive vice president directly owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. This represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.38% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

COR has been the subject of a number of research analyst reports. Evercore restated an “outperform” rating and issued a $350.00 price target (up from $330.00) on shares of Cencora in a research note on Thursday, August 6th. Argus increased their price objective on shares of Cencora from $340.00 to $380.00 and gave the company a “buy” rating in a research note on Tuesday, October 20th. UBS Group decreased their price objective on shares of Cencora from $430.00 to $400.00 and set a “buy” rating for the company in a report on Friday, October 16th. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Citigroup reissued a “buy” rating on shares of Cencora in a report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $366.44.

Cencora Company Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.